INDEMNIFICATION AGREEMENTIndemnification Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 20 between Editas Medicine, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
ContractEditas Medicine, Inc. • October 16th, 2015 • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
EDITAS MEDICINE, INC. Incentive Stock Option Agreement Granted Under 2013 Stock Incentive PlanIncentive Stock Option Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
EDITAS MEDICINE, INC. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Early Exercise)Nonstatutory Stock Option Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
EDITAS MEDICINE, INC. Restricted Stock Agreement Granted Under 2013 Stock Incentive PlanRestricted Stock Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
CONSENT TO SUBLEASELease • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
April 8, 2015 Sandra GlucksmannEditas Medicine, Inc. • October 16th, 2015 • Biological products, (no disgnostic substances) • Massachusetts
This letter amends and restates the employment letter dated September 19, 2013 between you and Editas Medicine, Inc. (the “Company”) (the “Prior Agreement”). Effective upon the date of this Agreement (the “Effective Date”), your continued employment with the Company shall be on the terms set forth in this Agreement and the Prior Agreement shall be terminated and of no further force or effect.
June 12, 2014Invention and Non-Disclosure Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • California
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of the date set forth above (the “Effective Date”) by and between SILICON VALLEY BANK (“Bank”), and the borrower named above (“Borrower”). Capitalized terms used but not otherwise defined herein shall have the meanings given them on Schedule C, The parties agree as follows:
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: A221317 MGH Case Nos: [**]Patent License Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“Agreement”) is made as of the 29th day of August, 2014 (“Effective Date”), by and between Editas Medicine, Inc., a Delaware corporation, with its principal place of business located at 300 Third Street, Cambridge, MA 02142 (“Company”), and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS Agreement is entered into this 10th day of October, 2014 (“Effective Date”) between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”), having a place of business at Durham, North Carolina 27710, and Editas Medicine, Inc., a corporation organized under the laws of the State of Delaware (“Licensee”), having its principal office at 300 Third Street, First Floor, Cambridge, MA 02142. Duke or Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”.
EDITAS MEDICINE, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 4, 2015Investors’ Rights Agreement • October 16th, 2015 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 4th day of August, 2015, by and among Editas Medicine, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Editas Medicine, Inc. • October 16th, 2015 • Biological products, (no disgnostic substances)
